NCT02724917暂停1 期
A Phase 1b/2a, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
CoMentis1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via adverse events
研究概览
简要总结
The purpose of this study in patients with schizophrenia is to evaluate the safety, tolerability, and pharmacokinetics of 3 doses (low, mid, high) of APN1125 compared with placebo when administered as repeated daily oral doses.
详细描述
The purpose of this study is to evaluate the safety profile, tolerability and pharmacokinetics (PK) of APN1125 following 14 days of once-daily oral dosing in subjects with schizophrenia on stable second-generation antipsychotic therapy.
This is a randomized, double-blind, 2-week, multiple ascending dose study of APN1125. This study will enroll up to three sequential cohorts of subjects diagnosed with schizophrenia, each randomly assigned to receive one of three doses (low, medium, or high) of APN1125 or matching placebo. Following admission to an Early Phase Clinical Unit (EPCU), APN1125 will be administered once daily for 2 weeks. All subjects will remain confined to the EPCU for a total of 20 days, consisting of admission, dosing and observation periods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females of any race
- •18 to 45 years of age, inclusive
- •Diagnosed with schizophrenia, as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), in a non-acute (e.g., chronic) phase and clinically stable for at least 12 weeks before screening
- •Currently on a stable second-generation anti-psychotic regimen (stable dose and medication for 12 weeks)
- •Subjects (male and female) of childbearing potential must use two effective methods of contraception starting from the time of providing informed consent throughout the duration of the study and for 3 months after discharge
- •Women of childbearing potential must have a negative pregnancy test at screening and at admission
排除标准
- •Clinically significant abnormal serum electrolytes (sodium, potassium, calcium, and magnesium) after repeat testing
- •Insulin-dependent diabetes or insufficiently controlled diabetes mellitus in the judgment of the Investigator
- •Renal insufficiency with serum creatinine >1.6 mg/dL Malignant tumor within the 5 years before Screening with the exception of treated squamous and basal cell carcinoma, cervical carcinoma in situ, or brachytherapy for localized prostate cancer
- •Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study
- •Unstable medical condition that is clinically significant in the judgment of the Investigator
- •Body mass index (BMI) >38 kg/m^2 at Screening ALT or AST >1.5 times the upper limit of normal
- •Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) 1 and/or 2 antibodies
- •Untreated clinically significant hypo- or hyperthyroidism; treated hypo- or hyperthyroidism should be stable for at least 8 weeks prior to Screening
- •History of myocardial infarction or unstable angina within 6 months before Screening
- •Cardiovascular disease history including symptomatic hypotension (supine systolic blood pressure [SBP] <90 mmHg or supine diastolic blood pressure [DBP] <60 mmHg), symptomatic orthostatic hypotension (orthostatic change in SBP >20 mmHg or DBP >15 mmHg), or hypertension (supine SBP >160 mmHg or supine DBP >95 mmHg ) or significant cardiac arrhythmia (in the judgment of the Investigator)
- •Clinically significant abnormality on Screening or Baseline electrocardiogram (ECG), including but not necessarily limited to a confirmed QTcF (QT interval corrected for heart rate using Fridericia's formula) interval value >450 msec for males or >470 msec for females
- •Current treatment with more than 2 atypical antipsychotics Psychiatric hospitalization due to breakthrough psychotic symptoms or acute exacerbations within 3 months before Day -
- •Subjects with a recent "social" hospitalization may be screened after consultation with the Medical Monitor.
- •Subjects with other DSM-5 disorders are ineligible if the comorbid condition is clinically unstable or has been the primary focus of treatment within 3 months prior to Screening
- •Subjects meeting DSM-5 criteria for moderate to severe alcohol or substance use disorder (other than nicotine- or caffeine-related disorders) within 6 months prior to Screening
- •Urine drug screen (UDS) positive for drugs of abuse (excluding prescribed benzodiazepines) or positive alcohol breath test at Screening and/or Baseline (may be repeated once if, in the judgment of the Investigator, the subject does not meet DSM-5 criteria for moderate to severe substance abuse disorder)
- •Significant suicide risk as defined by 1) suicidal ideations as endorsed on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the year prior to Screening or Baseline, 2) suicidal behaviors within the 2 years prior to Screening, or 3) Investigator assessment
- •History of stroke, brain tumor, subdural hematoma, Parkinson's Disease, dementia or other clinically significant neurological condition
- •Head trauma with loss of consciousness within 12 months prior to Screening
- •Active acute or chronic CNS infection
- •History of a seizure disorder
- •Immunosuppressants, including systemic corticosteroids (administered at an immunosuppressant dose in the judgment of the Investigator) (Note: Inhaled, nasal, or topical steroid use for allergy or other inflammation is permitted)
- •Any drugs with CNS activity (Note: Occasional (as needed) use of a sedative-hypnotic (e.g., benzodiazepine or nonbenzodiazepine [e.g., zolpidem, zaleplon, zopiclone, and eszopiclone]) as a sleep aid and stable second generation psychotics are permitted)
- •Prohibited antipsychotic medications (e.g., clozapine or typical, first-generation antipsychotics)
- •Excessive alcohol consumption (regular alcohol intake 14 units per week or more) or has a history of alcohol use disorder. Use of alcohol up to 48 hours before admission to the EPCU is not allowed.
- •Failure or inability to perform Screening or Baseline assessments
- •Exposure to an experimental drug or experimental medical device within 2 months before Screening, or an experimental biologic within 3 months before Screening
研究组 & 干预措施
APN1125, Low Dose
Experimental
APN1125, Low Dose
干预措施: APN1125 (Drug)
APN1125, Mid Dose
Experimental
APN1125, Mid Dose
干预措施: APN1125 (Drug)
APN1125, High Dose
Experimental
APN1125, High Dose
干预措施: APN1125 (Drug)
Placebo
Placebo Comparator
Placebo to match
干预措施: Placebo (Drug)
结局指标
主要结局
Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via adverse events
时间窗: 25 days
Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via clinical laboratory tests (chemistry, hematology, coagulation and urinalysis)
时间窗: 25 days
Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via vital signs (e.g., blood pressure, pulse rate, respiratory rate, oral temperature)
时间窗: 25 days
Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via ECGs
时间窗: 25 days
Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via physical exams
时间窗: 25 days
次要结局
- Maximum observed plasma APN1125 concentration (Cmax)(Days 1 and 14)
- Time corresponding to occurrence of Cmax (Tmax)(Days 1 and 14)
- Area under the Curve from time zero to the last quantifiable plasma APN1125 concentration (AUClast)(Days 1 and 14)
- Area under the Curve from time zero extrapolated to plasma APN1125 concentration at infinity (AUCinf)(Days 1 and 14)
- Terminal plasma APN1125 rate constant (lambda z)(Days 1 and 14)
- Apparent plasma APN1125 terminal half-life (t1/2)(Days 1 and 14)
- Apparent APN1125 plasma clearance (CL/F)(Days 1 and 14)
- Amount of unmetabolized APN1125 excreted in urine (Ae)(Days 1 and 14)
- Fraction of unmetabolized APN1125 dose excreted in urine (Fe)(Days 1 and 14)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)Autism Spectrum DisorderNCT04644003Stalicla SA12
已完成
1 期
A Study of LY3532226 in Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT05407961Eli Lilly and Company90
终止
2 期
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney DiseaseGoutChronic Kidney DiseasesHyperuricemiaNCT04987294Allena Pharmaceuticals19
已完成
2 期
Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and FrequencyOveractive BladderNCT01294982American Oriental Bioengineering, Inc.66
已完成
2 期
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected PatientsHIV InfectionsNCT00071097Tibotec Pharmaceuticals, Ireland330